Stock Analysis on Net

Abbott Laboratories (NYSE:ABT) 

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Abbott Laboratories, consolidated cash flow statement

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings 13,402 5,723 6,933 7,071 4,495
Depreciation 1,340 1,277 1,254 1,491 1,195
Amortization of intangible assets 1,878 1,966 2,013 2,047 2,132
Share-based compensation 673 644 685 640 546
Investing and financing losses, net 482 126 215 55 425
Trade receivables (691) (356) (68) (383) (924)
Inventories (58) (232) (1,413) (456) (493)
Prepaid expenses and other assets (796) (542) (75) (312) (627)
Trade accounts payable and other liabilities 356 (760) 420 1,288 1,766
Income taxes (8,028) (585) (383) (908) (614)
(Increase) decrease in operating capital (9,217) (2,475) (1,519) (771) (892)
Adjustments to reconcile earnings to net cash from operating activities (4,844) 1,538 2,648 3,462 3,406
Net cash from operating activities 8,558 7,261 9,581 10,533 7,901
Acquisitions of property and equipment (2,207) (2,202) (1,777) (1,885) (2,177)
Acquisitions of businesses and technologies, net of cash acquired (877) (187) (42)
Proceeds from business dispositions 1 40 48 134 58
Purchases of investment securities (169) (159) (185) (173) (83)
Proceeds from sales of investment securities 28 43 152 77 10
Other 9 22 22 26 19
Net cash used in investing activities (2,338) (3,133) (1,740) (2,008) (2,215)
Proceeds from issuance (repayments) of short-term debt, net and other (100) 21 47 (204) 2
Proceeds from issuance of long-term debt and debt with maturities over 3 months 223 2 7 4 1,281
Repayments of long-term debt and debt with maturities over 3 months (660) (2,498) (753) (48) (1,333)
Purchases of common shares (1,295) (1,227) (3,795) (2,299) (403)
Proceeds from stock options exercised 264 167 167 255 245
Dividends paid (3,836) (3,556) (3,309) (3,202) (2,560)
Other (11)
Net cash used in financing activities (5,404) (7,091) (7,636) (5,494) (2,779)
Effect of exchange rate changes on cash and cash equivalents (96) (23) (122) (70) 71
Net increase (decrease) in cash and cash equivalents 720 (2,986) 83 2,961 2,978
Cash and cash equivalents, beginning of year 6,896 9,882 9,799 6,838 3,860
Cash and cash equivalents, end of year 7,616 6,896 9,882 9,799 6,838

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Cash flow statement item Description The company
Net cash from operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Abbott Laboratories net cash from operating activities decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Abbott Laboratories net cash used in investing activities decreased from 2022 to 2023 but then increased from 2023 to 2024 not reaching 2022 level.
Net cash used in financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Abbott Laboratories net cash used in financing activities increased from 2022 to 2023 and from 2023 to 2024.